Active	Status	Sponsor type	Region	Phase	Filter
9 Active 8 Inactive 17 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Dunn, Michael
EBONI, NCT05514509: A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories	Active, not recruiting	4	66	US	APRETUDE, Cabotegravir tablet	ViiV Healthcare	HIV Infections	09/25	09/25
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension	Completed	3	1083	Europe, Canada, US, RoW	Placebo, lorundrostat Dose 1, lorundrostat Dose 2	Mineralys Therapeutics Inc.	Hypertension	12/24	01/25
NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension	Enrolling by invitation	3	1400	Europe, Canada, US, RoW	lorundrostat, Placebo	Mineralys Therapeutics Inc.	Hypertension	12/25	12/26
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen	Completed	2	285	US	Placebo, lorundrostat Dose 1, lorundrostat Dose 2	Mineralys Therapeutics Inc.	Hypertension	01/25	01/25
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults	Completed	2	797	NA	ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline	AEON Biopharma, Inc., PPD	Migraine	06/24	08/24
FrAILT, NCT03228290: Functional Assessment in Liver Transplantation	Recruiting	N/A	5000	US		University of California, San Francisco, National Institute on Aging (NIA), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	End Stage Liver Disease	12/28	12/28
ECALC, NCT05616247: Efficacy of the Expectancy Challenge Alcohol Literacy Curriculum on Reducing College Student Alcohol Use and Harms	Enrolling by invitation	N/A	360	US	ECALC, ECALC Plus Weekly Boosters	University of Central Florida	Alcohol Use, Underage, Harmful; Use, Alcohol	05/25	09/25
Olan, Elizabeth
MODEL, NCT05516992: Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine	Active, not recruiting	3	417	US	SB-01 For Injection, Sham Needle	Spine BioPharma, Inc, MCRA	Lumbar Degenerative Disc Disease	02/25	08/25
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults	Completed	2	797	NA	ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline	AEON Biopharma, Inc., PPD	Migraine	06/24	08/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Dunn, Michael
EBONI, NCT05514509: A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories	Active, not recruiting	4	66	US	APRETUDE, Cabotegravir tablet	ViiV Healthcare	HIV Infections	09/25	09/25
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension	Completed	3	1083	Europe, Canada, US, RoW	Placebo, lorundrostat Dose 1, lorundrostat Dose 2	Mineralys Therapeutics Inc.	Hypertension	12/24	01/25
NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension	Enrolling by invitation	3	1400	Europe, Canada, US, RoW	lorundrostat, Placebo	Mineralys Therapeutics Inc.	Hypertension	12/25	12/26
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen	Completed	2	285	US	Placebo, lorundrostat Dose 1, lorundrostat Dose 2	Mineralys Therapeutics Inc.	Hypertension	01/25	01/25
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults	Completed	2	797	NA	ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline	AEON Biopharma, Inc., PPD	Migraine	06/24	08/24
FrAILT, NCT03228290: Functional Assessment in Liver Transplantation	Recruiting	N/A	5000	US		University of California, San Francisco, National Institute on Aging (NIA), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	End Stage Liver Disease	12/28	12/28
ECALC, NCT05616247: Efficacy of the Expectancy Challenge Alcohol Literacy Curriculum on Reducing College Student Alcohol Use and Harms	Enrolling by invitation	N/A	360	US	ECALC, ECALC Plus Weekly Boosters	University of Central Florida	Alcohol Use, Underage, Harmful; Use, Alcohol	05/25	09/25
Olan, Elizabeth
MODEL, NCT05516992: Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar Spine	Active, not recruiting	3	417	US	SB-01 For Injection, Sham Needle	Spine BioPharma, Inc, MCRA	Lumbar Degenerative Disc Disease	02/25	08/25
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults	Completed	2	797	NA	ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline	AEON Biopharma, Inc., PPD	Migraine	06/24	08/24